ABBOTT LABORATORIES
10-Qs and 10-Ks
PROXIES
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
10-Q
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
For the quarterly period ended
March 31, 2023
OR
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
For the transition period from to
Commission File No.
1-2189
|
An
|
I.R.S. Employer Identification No. | ||||
|
|
|||||
Telephone:
(
224
)
667-6100
Securities Registered Pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||
|
|
|
|
||||||
Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes
x
No
o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes
x
No
o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
Accelerated Filer
o
|
||||
|
Non-Accelerated Filer
o
|
|
||||
|
|
|||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
o
No
x
As of March 31, 2023, Abbott Laboratories had
1,738,946,799
common shares without par value outstanding.
Abbott Laboratories
Table of Contents
| Page | |||||
2
Abbott Laboratories and Subsidiaries
Cond
ensed Consolidated Statement of Earnings
(Unaudited)
(dollars in millions except per share data; shares in thousands)
| Three Months Ended | |||||||||||
| March 31 | |||||||||||
| 2023 | 2022 | ||||||||||
| Net sales | $ |
|
$ |
|
|||||||
| Cost of products sold, excluding amortization of intangible assets |
|
|
|||||||||
| Amortization of intangible assets |
|
|
|||||||||
| Research and development |
|
|
|||||||||
| Selling, general and administrative |
|
|
|||||||||
| Total operating cost and expenses |
|
|
|||||||||
| Operating earnings |
|
|
|||||||||
| Interest expense |
|
|
|||||||||
| Interest (income) |
(
|
(
|
|||||||||
| Net foreign exchange (gain) loss |
|
(
|
|||||||||
| Other (income) expense, net |
(
|
(
|
|||||||||
| Earnings before taxes |
|
|
|||||||||
| Taxes on earnings |
|
|
|||||||||
| Net Earnings | $ |
|
$ |
|
|||||||
| Basic Earnings Per Common Share | $ |
|
$ |
|
|||||||
| Diluted Earnings Per Common Share | $ |
|
$ |
|
|||||||
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share |
|
|
|||||||||
| Dilutive Common Stock Options |
|
|
|||||||||
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options |
|
|
|||||||||
| Outstanding Common Stock Options Having No Dilutive Effect |
|
|
|||||||||
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
3
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Comprehensive Income
(U
naudited)
(dollars in mill
ions)
| Three Months Ended | |||||||||||
| March 31 | |||||||||||
| 2023 | 2022 | ||||||||||
| Net Earnings | $ |
|
$ |
|
|||||||
| Foreign currency translation gain (loss) adjustments |
|
(
|
|||||||||
|
Net actuarial gains (losses) and amortization of net actuarial losses and prior service costs and credits, net of taxes of $
|
|
|
|||||||||
|
Net gains (losses) for derivative instruments designated as cash flow hedges and other, net of taxes of $(
|
(
|
(
|
|||||||||
| Other comprehensive income (loss) |
|
(
|
|||||||||
| Comprehensive Income | $ |
|
$ |
|
|||||||
|
March 31,
2023 |
December 31,
2022 |
||||||||||
| Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: | |||||||||||
| Cumulative foreign currency translation (loss) adjustments | $ |
(
|
$ |
(
|
|||||||
| Net actuarial (losses) and prior service (costs) and credits |
(
|
(
|
|||||||||
| Cumulative gains (losses) on derivative instruments designated as cash flow hedges |
|
|
|||||||||
| Accumulated Other Comprehensive Income (Loss) | $ |
(
|
$ |
(
|
|||||||
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
4
Abbott Laboratories and Subsidiaries
Condensed Consolidated Balance Sheet
(Unaudited)
(dollars in
millions)
|
March 31,
2023 |
December 31,
2022 |
||||||||||
| Assets | |||||||||||
| Current Assets: | |||||||||||
| Cash and cash equivalents | $ |
|
$ |
|
|||||||
| Short-term investments |
|
|
|||||||||
|
Trade receivables, less allowances of $
|
|
|
|||||||||
| Inventories: | |||||||||||
| Finished products |
|
|
|||||||||
| Work in process |
|
|
|||||||||
| Materials |
|
|
|||||||||
| Total inventories |
|
|
|||||||||
| Prepaid expenses and other receivables |
|
|
|||||||||
| Total Current Assets |
|
|
|||||||||
| Investments |
|
|
|||||||||
| Property and equipment, at cost |
|
|
|||||||||
| Less: accumulated depreciation and amortization |
|
|
|||||||||
| Net property and equipment |
|
|
|||||||||
| Intangible assets, net of amortization |
|
|
|||||||||
| Goodwill |
|
|
|||||||||
| Deferred income taxes and other assets |
|
|
|||||||||
| $ |
|
$ |
|
||||||||
| Liabilities and Shareholders’ Investment | |||||||||||
| Current Liabilities: | |||||||||||
| Trade accounts payable | $ |
|
$ |
|
|||||||
| Salaries, wages and commissions |
|
|
|||||||||
| Other accrued liabilities |
|
|
|||||||||
| Dividends payable |
|
|
|||||||||
| Income taxes payable |
|
|
|||||||||
| Current portion of long-term debt |
|
|
|||||||||
| Total Current Liabilities |
|
|
|||||||||
| Long-term debt |
|
|
|||||||||
| Post-employment obligations, deferred income taxes and other long-term liabilities |
|
|
|||||||||
| Commitments and Contingencies |
|
|
|||||||||
| Shareholders’ Investment: | |||||||||||
|
Preferred shares,
|
|
|
|||||||||
|
Common shares, without par value Authorized —
Issued at stated capital amount — Shares: 2023:
|
|
|
|||||||||
|
Common shares held in treasury, at cost — Shares: 2023:
|
(
|
(
|
|||||||||
| Earnings employed in the business |
|
|
|||||||||
| Accumulated other comprehensive income (loss) |
(
|
(
|
|||||||||
| Total Abbott Shareholders’ Investment |
|
|
|||||||||
| Noncontrolling Interests in Subsidiaries |
|
|
|||||||||
| Total Shareholders’ Investment |
|
|
|||||||||
| $ |
|
$ |
|
||||||||
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
5
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Shareholders’ Investment
(Unaudited)
(in millions except shares and per share data)
| Three Months Ended March 31 | |||||||||||
| 2023 | 2022 | ||||||||||
| Common Shares: | |||||||||||
| Balance at January 1 | |||||||||||
|
Shares: 2023:
|
$ |
|
$ |
|
|||||||
| Issued under incentive stock programs | |||||||||||
|
Shares: 2023:
|
|
|
|||||||||
| Share-based compensation |
|
|
|||||||||
| Issuance of restricted stock awards |
(
|
(
|
|||||||||
| Balance at March 31 | |||||||||||
|
Shares: 2023:
|
$ |
|
$ |
|
|||||||
| Common Shares Held in Treasury: | |||||||||||
| Balance at January 1 | |||||||||||
|
Shares: 2023:
|
$ |
(
|
$ |
(
|
|||||||
| Issued under incentive stock programs | |||||||||||
|
Shares: 2023:
|
|
|
|||||||||
| Purchased | |||||||||||
|
Shares: 2023:
|
(
|
(
|
|||||||||
| Balance at March 31 | |||||||||||
|
Shares: 2023:
|
$ |
(
|
$ |
(
|
|||||||
| Earnings Employed in the Business: | |||||||||||
| Balance at January 1 | $ |
|
$ |
|
|||||||
| Net earnings |
|
|
|||||||||
|
Cash dividends declared on common shares (per share — 2023: $
|
(
|
(
|
|||||||||
| Effect of common and treasury share transactions |
|
|
|||||||||
| Balance at March 31 | $ |
|
$ |
|
|||||||
| Accumulated Other Comprehensive Income (Loss): | |||||||||||
| Balance at January 1 | $ |
(
|
$ |
(
|
|||||||
| Other comprehensive income (loss) |
|
(
|
|||||||||
| Balance at March 31 | $ |
(
|
$ |
(
|
|||||||
| Noncontrolling Interests in Subsidiaries: | |||||||||||
| Balance at January 1 | $ |
|
$ |
|
|||||||
| Noncontrolling Interests’ share of income, business combinations, net of distributions and share repurchases |
|
|
|||||||||
| Balance at March 31 | $ |
|
$ |
|
|||||||
The accompanying notes to condensed consolidated financial statements are an integral part of this statement.
6
Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Cash Flows
(
Unaudited)
(dollars in
millions)
| Three Months Ended March 31 | |||||||||||
| 2023 | 2022 | ||||||||||
| Cash Flow From (Used in) Operating Activities: | |||||||||||
| Net earnings | $ |
|
$ |
|
|||||||
| Adjustments to reconcile net earnings to net cash from operating activities — | |||||||||||
| Depreciation |
|
|
|||||||||
| Amortization of intangible assets |
|
|
|||||||||
| Share-based compensation |
|
|
|||||||||
| Trade receivables |
|
(
|
|||||||||
| Inventories |
(
|
(
|
|||||||||
| Other, net |
(
|
(
|
|||||||||
| Net Cash From Operating Activities |
|
|
|||||||||
| Cash Flow From (Used in) Investing Activities: | |||||||||||
| Acquisitions of property and equipment |
(
|
(
|
|||||||||
| Sales (purchases) of other investment securities, net |
(
|
(
|
|||||||||
| Other |
|
|
|||||||||
| Net Cash From (Used in) Investing Activities |
(
|
(
|
|||||||||
| Cash Flow From (Used in) Financing Activities: | |||||||||||
| Net borrowings (repayments) of short-term debt and other |
(
|
|
|||||||||
| Repayments of long-term debt |
|
(
|
|||||||||
| Purchases of common shares |
(
|
(
|
|||||||||
| Proceeds from stock options exercised |
|
|
|||||||||
| Dividends paid |
(
|
(
|
|||||||||
| Net Cash From (Used in) Financing Activities |
(
|
(
|
|||||||||
| Effect of exchange rate changes on cash and cash equivalents |
|
(
|
|||||||||
| Net Increase (Decrease) in Cash and Cash Equivalents |
(
|
(
|
|||||||||
| Cash and Cash Equivalents, Beginning of Year |
|
|
|||||||||
| Cash and Cash Equivalents, End of Period | $ |
|
$ |
|
|||||||
The accompanying notes to the condensed consolidated financial statements are an integral part of this statement.
7
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 1 — Basis of Presentation
The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2022. The condensed consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.
Note 2 — New Accounting Standards
Recent Adopted Accounting Standards
In September 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 2022-04, Disclosure of Supplier Finance Program Obligations, which requires an entity to report information about its supplier finance program. Abbott adopted the standard on January 1, 2023. The new standard did not have an impact on Abbott's condensed consolidated financial statements.
8
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 3 — Revenue
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Abbott has
four
reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
The following tables provide detail by sales category:
| Three Months Ended March 31, 2023 | Three Months Ended March 31, 2022 | |||||||||||||||||||||||||||||||||||||
| (in millions) | U.S. | Int’l | Total | U.S. | Int’l | Total | ||||||||||||||||||||||||||||||||
| Established Pharmaceutical Products — | ||||||||||||||||||||||||||||||||||||||
| Key Emerging Markets | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Other |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Nutritionals — | ||||||||||||||||||||||||||||||||||||||
| Pediatric Nutritionals |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Adult Nutritionals |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Diagnostics — | ||||||||||||||||||||||||||||||||||||||
| Core Laboratory |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Molecular |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Point of Care |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Rapid Diagnostics |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Medical Devices — | ||||||||||||||||||||||||||||||||||||||
| Rhythm Management |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Electrophysiology |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Heart Failure |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Vascular |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Structural Heart |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Neuromodulation |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Diabetes Care |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Other |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
Remaining Performance Obligations
As of March 31, 2023, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $
4.1
billion in the Diagnostics segment and approximately $
450
million in the Medical Devices segment. Abbott expects to recognize revenue on approximately
60
percent of these remaining performance obligations over the next
24
months, approximately
17
percent over the subsequent
12
months and the remainder thereafter.
9
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 3 — Revenue (Continued)
These performance obligations primarily reflect the future sale of reagents/consumables in contracts with minimum purchase obligations, extended warranty or service obligations related to previously sold equipment, and remote monitoring services related to previously implanted devices. Abbott has applied the practical expedient described in FASB Accounting Standards Codification (ASC) 606-10-50-14 and has not included remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.
Other Contract Assets and Liabilities
Abbott discloses Trade receivables separately in the Condensed Consolidated Balance Sheet at the net amount expected to be collected. Contract assets primarily relate to Abbott’s conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Abbott’s contract liabilities arise primarily in the Medical Devices reportable segment when payment is received upfront for various multi-period extended service arrangements.
Changes in the contract liabilities during the period are as follows:
| (in millions) | ||||||||
| Contract Liabilities: | ||||||||
| Balance at December 31, 2022 | $ |
|
||||||
| Unearned revenue from cash received during the period |
|
|||||||
| Revenue recognized related to contract liability balance |
(
|
|||||||
| Balance at March 31, 2023 | $ |
|
||||||
Note 4 — Supplemental Financial Information
Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Net earnings allocated to common shares for the three months ended March 31, 2023 and 2022 were $
1.313
billion and $
2.438
billion, respectively.
Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2023 includes $
282
million of pension contributions and the payment of cash taxes of approximately $
122
million. The first three months of 2022 includes $
334
million of pension contributions and the payment of cash taxes of approximately $
195
million.
The following summarizes the activity for the first three months of 2023 related to the allowance for doubtful accounts as of March 31, 2023:
| (in millions) | ||||||||
| Allowance for Doubtful Accounts: | ||||||||
| Balance at December 31, 2022 | $ |
|
||||||
| Provisions/charges to income |
|
|||||||
| Amounts charged off and other adjustments |
|
|||||||
| Balance at March 31, 2023 | $ |
|
||||||
10
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 4 — Supplemental Financial Information (Continued)
The allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of the accounts receivable. Abbott considers various factors in establishing, monitoring, and adjusting its allowance for doubtful accounts, including the aging of the accounts and aging trends, the historical level of charge-offs, and specific exposures related to particular customers. Abbott also monitors other risk factors and forward-looking information, such as country risk, when determining credit limits for customers and establishing adequate allowances.
The components of long-term investments as of March 31, 2023 and December 31, 2022 are as follows:
| (in millions) |
March 31,
2023 |
December 31,
2022 |
||||||||||||
| Long-term Investments: | ||||||||||||||
| Equity securities | $ |
|
$ |
|
||||||||||
| Other |
|
|
||||||||||||
| Total | $ |
|
$ |
|
||||||||||
The increase in Abbott’s long-term investments as of March 31, 2023 versus the balance as of December 31, 2022 primarily relates to an increase in the value of securities held in a rabbi trust and additional investments,
partially offset by equity method investment losses.
Abbott’s equity securities as of March 31, 2023, include $
305
million of investments in mutual funds that are held in a rabbi trust and were acquired as part of the St. Jude Medical, Inc. (St. Jude Medical) business acquisition. These investments, which are specifically designated as available for the purpose of paying benefits under a deferred compensation plan, are not available for general corporate purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of March 31, 2023 with a carrying value of $
162
million that are accounted for under the equity method of accounting and other equity investments with a carrying value of approximately $
88
million that do not have a readily determinable fair value.
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
| Three Months Ended March 31 | ||||||||||||||||||||||||||||||||||||||
|
Cumulative Foreign
Currency Translation (Loss) Adjustments |
Net Actuarial (Losses) and
Prior Service (Costs) and Credits |
Cumulative Gains (Losses)
on Derivative Instruments Designated as Cash Flow Hedges and Other |
||||||||||||||||||||||||||||||||||||
| (in millions) | 2023 | 2022 | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||||||||||||
| Balance at January 1 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications |
|
(
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Amounts reclassified from accumulated other comprehensive income |
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Net current period comprehensive income (loss) |
|
(
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Balance at March 31 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
||||||||||||||||||||||||||
11
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss) (Continued)
Note 6 — Goodwill and Intangible Assets
The total amount of goodwill reported was $
22.9
billion at March 31, 2023 and $
22.8
billion at December 31, 2022. Foreign currency translation adjustments increased goodwill by approximately $
128
million in the first three months of 2023. The amount of goodwill related to reportable segments at March 31, 2023 was $
2.7
billion for the Established Pharmaceutical Products segment, $
286
million for the Nutritional Products segment, $
3.5
billion for the Diagnostic Products segment, and $
16.4
billion for the Medical Devices segment. There was
no
reduction of goodwill relating to impairments in the first three months of 2023.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $
27.4
billion and $
27.2
billion as of March 31, 2023 and December 31, 2022, respectively. Accumulated amortization was $
18.2
billion and $
17.6
billion as of March 31, 2023 and December 31, 2022, respectively. Foreign currency translation adjustments increased intangible assets by $
43
million in the first three months of 2023. Abbott’s estimated annual amortization expense for intangible assets is approximately $
2.0
billion in 2023, $
1.9
billion in 2024, $
1.7
billion in 2025, $
1.5
billion in 2026 and $
1.2
billion in 2027.
Indefinite-lived intangible assets, which relate to in-process R&D (IPR&D) acquired in a business combination, were approximately $
807
million as of March 31, 2023 and December 31, 2022.
Note 7 — Restructuring Plans
In 2022 and 2023, Abbott management approved various plans to streamline operations in order to reduce costs and improve efficiencies in its medical devices, nutritional, diagnostic, and established pharmaceutical businesses. In the first three months of 2023, Abbott recorded employee related severance and other charges of approximately $
17
million, of which approximately $
6
million was recorded in Cost of products sold, and approximately $
11
million was recorded in Selling, general and administrative expenses.
The following summarizes the activity related to these restructuring actions and the status of the related accruals as of March 31, 2023:
| (in millions) | ||||||||
| Accrued balance at December 31, 2022 | $ |
|
||||||
| Restructuring charges in 2023 |
|
|||||||
| Payments and other adjustments |
(
|
|||||||
| Accrued balance at March 31, 2023 | $ |
|
||||||
12
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 8 — Incentive Stock Programs
In the first three months of 2023, Abbott granted
1,887,093
stock options,
445,278
restricted stock awards and
4,761,433
restricted stock units under its incentive stock program. At March 31, 2023, approximately
74
million shares were reserved for future grants.
Information regarding the number of options outstanding and exercisable at March 31, 2023 is as follows:
| Outstanding | Exercisable | |||||||||||||
| Number of shares |
|
|
||||||||||||
|
Weighted average remaining life
(years)
|
|
|
||||||||||||
| Weighted average exercise price | $ |
|
$ |
|
||||||||||
|
Aggregate intrinsic value
(in millions)
|
$ |
|
$ |
|
||||||||||
The total unrecognized share-based compensation cost at March 31, 2023 amounted to approximately $
760
million, which is expected to be recognized over the next
three years
.
Note 9 — Debt and Lines of Credit
On March 15, 2022, Abbott repaid the $
750
million outstanding principal amount of its
2.55
% Notes upon maturity.
Note 10 — Financial Instruments, Derivatives and Fair Value Measures
Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates, primarily for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $
7.1
billion at March 31, 2023 and $
7.7
billion at December 31, 2022, are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2023 will be included in Cost of products sold at the time the products are sold, generally through the next
to
eighteen months
.
Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2023 and December 31, 2022, Abbott held the gross notional amounts of $
11.4
billion and $
12.0
billion, respectively, of such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated,
5
-year term loan of approximately $
451
million and $
446
million as of March 31, 2023 and December 31, 2022, respectively, as a hedge of the net investment in certain foreign subsidiaries. The change in the value of the debt, which is due to changes in foreign exchange rates, is recorded in Accumulated other comprehensive income (loss), net of tax.
Abbott is a party to interest rate hedge contracts with a notional amount totaling approximately $
2.9
billion at March 31, 2023 and December 31, 2022 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.
13
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2023 and December 31, 2022:
| Fair Value - Assets | Fair Value - Liabilities | |||||||||||||||||||||||||||||||||||||
| (in millions) |
March 31,
2023 |
December 31,
2022 |
Balance Sheet Caption |
March 31,
2023 |
December 31,
2022 |
Balance Sheet Caption | ||||||||||||||||||||||||||||||||
| Interest rate swaps designated as fair value hedges: | ||||||||||||||||||||||||||||||||||||||
| Non-current | $ |
|
$ |
|
Deferred income taxes and other assets | $ |
|
$ |
|
Post-employment obligations, deferred income taxes and other long-term liabilities | ||||||||||||||||||||||||||||
| Current |
|
|
Prepaid expenses and other receivables |
|
|
Other accrued liabilities | ||||||||||||||||||||||||||||||||
| Foreign currency forward exchange contracts: | ||||||||||||||||||||||||||||||||||||||
| Hedging instruments |
|
|
Prepaid expenses and other receivables |
|
|
Other accrued liabilities | ||||||||||||||||||||||||||||||||
| Others not designated as hedges |
|
|
Prepaid expenses and other receivables |
|
|
Other accrued liabilities | ||||||||||||||||||||||||||||||||
| Debt designated as a hedge of net investment in a foreign subsidiary | — | — | n/a |
|
|
Long-term debt | ||||||||||||||||||||||||||||||||
| $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges and certain other derivative financial instruments, as well as the amounts and location of income (expense) and gain (loss) reclassified into income for the three months ended March 31, 2023 and 2022.
| Gain (loss) Recognized in Other Comprehensive Income (loss) |
Income (expense) and
Gain (loss) Reclassified into Income |
|||||||||||||||||||||||||||||||||||||
|
Three Months
Ended March 31 |
Three Months
Ended March 31 |
|||||||||||||||||||||||||||||||||||||
| (in millions) | 2023 | 2022 | 2023 | 2022 | Income Statement Caption | |||||||||||||||||||||||||||||||||
| Foreign currency forward exchange contracts designated as cash flow hedges | $ |
(
|
$ |
(
|
$ |
|
$ |
|
Cost of products sold | |||||||||||||||||||||||||||||
| Debt designated as a hedge of net investment in a foreign subsidiary |
(
|
|
— | — | n/a | |||||||||||||||||||||||||||||||||
| Interest rate swaps designated as fair value hedges | n/a | n/a |
|
(
|
Interest expense | |||||||||||||||||||||||||||||||||
14
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
Losses of $
103
million and $
51
million were recognized in the three months ended March 31, 2023 and 2022, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange (gain) loss line.
The carrying values and fair values of certain financial instruments as of March 31, 2023 and December 31, 2022 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from non-performance by these counterparties.
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||
| (in millions) |
Carrying
Value |
Fair
Value |
Carrying
Value |
Fair
Value |
||||||||||||||||||||||
| Long-term Investment Securities: | ||||||||||||||||||||||||||
| Equity securities | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Other |
|
|
|
|
||||||||||||||||||||||
| Total Long-term Debt |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Foreign Currency Forward Exchange Contracts: | ||||||||||||||||||||||||||
| Receivable position |
|
|
|
|
||||||||||||||||||||||
| (Payable) position |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Interest Rate Hedge Contracts: | ||||||||||||||||||||||||||
| (Payable) position |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.
15
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 10 — Financial Instruments, Derivatives and Fair Value Measures (Continued)
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
| Basis of Fair Value Measurement | ||||||||||||||||||||||||||
| (in millions) |
Outstanding
Balances |
Quoted
Prices in Active Markets |
Significant
Other Observable Inputs |
Significant
Unobservable Inputs |
||||||||||||||||||||||
| March 31, 2023: | ||||||||||||||||||||||||||
| Equity securities | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Foreign currency forward exchange contracts |
|
|
|
|
||||||||||||||||||||||
| Total Assets | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Fair value of hedged long-term debt | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Interest rate swap derivative financial instruments |
|
|
|
|
||||||||||||||||||||||
| Foreign currency forward exchange contracts |
|
|
|
|
||||||||||||||||||||||
| Contingent consideration related to business combinations |
|
|
|
|
||||||||||||||||||||||
| Total Liabilities | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| December 31, 2022: | ||||||||||||||||||||||||||
| Equity securities | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Foreign currency forward exchange contracts |
|
|
|
|
||||||||||||||||||||||
| Total Assets | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Fair value of hedged long-term debt | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Interest rate swap derivative financial instruments |
|
|
|
|
||||||||||||||||||||||
| Foreign currency forward exchange contracts |
|
|
|
|
||||||||||||||||||||||
| Contingent consideration related to business combinations |
|
|
|
|
||||||||||||||||||||||
| Total Liabilities | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis using significant other observable inputs. The fair value of the contingent consideration was determined based on independent appraisals at the time of acquisition, adjusted for the time value of money and other changes in fair value.
Note 11 — Litigation and Environmental Matters
Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $
4
million, and the aggregate cleanup exposure is not expected to exceed $
10
million.
16
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 11 — Litigation and Environmental Matters (Continued)
Note 12 — Post-Employment Benefits
Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net periodic benefit costs, other than service costs, are recognized in the Other (income) expense, net line of the Condensed Consolidated Statement of Earnings.
Net cost recognized for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:
| Defined Benefit Plans | Medical and Dental Plans | ||||||||||||||||||||||||||||
|
Three Months
Ended March 31 |
Three Months
Ended March 31 |
||||||||||||||||||||||||||||
| (in millions) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||
| Service cost - benefits earned during the period | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||
| Interest cost on projected benefit obligations |
|
|
|
|
|||||||||||||||||||||||||
| Expected return on plan assets |
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||
| Net amortization of: | |||||||||||||||||||||||||||||
| Actuarial loss, net |
|
|
|
|
|||||||||||||||||||||||||
| Prior service cost (credit) |
|
|
(
|
(
|
|||||||||||||||||||||||||
| Net cost (credit) | $ |
(
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||||||||
Note 13 — Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2023 and 2022, taxes on earnings include approximately $
3
million and $
30
million, respectively, in excess tax benefits associated with share-based compensation. In the first three months of 2023 and 2022, taxes on earnings also include approximately $
22
million and $
30
million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.
Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $
75
million to $
80
million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
17
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 14 — Segment Information
Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products
— International sales of a broad line of branded generic pharmaceutical products.
Nutritional Products
— Worldwide sales of a broad line of adult and pediatric nutritional products.
Diagnostic Products
— Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Rapid Diagnostics, Molecular Diagnostics and Point of Care Diagnostics divisions are aggregated and reported as the Diagnostic Products segment.
Medical Devices
— Worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. For segment reporting purposes, the Cardiac Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, Neuromodulation and Diabetes Care divisions are aggregated and reported as the Medical Devices segment.
Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets.
18
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2023
(Unaudited)
Note 14 — Segment Information (Continued)
The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.
| Net Sales to External Customers | Operating Earnings | |||||||||||||||||||||||||
|
Three Months
Ended March 31 |
Three Months
Ended March 31 |
|||||||||||||||||||||||||
| (in millions) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Established Pharmaceutical Products | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Nutritional Products |
|
|
|
|
||||||||||||||||||||||
| Diagnostic Products |
|
|
|
|
||||||||||||||||||||||
| Medical Devices |
|
|
|
|
||||||||||||||||||||||
| Total Reportable Segments |
|
|
|
|
||||||||||||||||||||||
| Other |
|
|
||||||||||||||||||||||||
| Net sales | $ |
|
$ |
|
||||||||||||||||||||||
| Corporate functions and benefit plan costs |
(
|
(
|
||||||||||||||||||||||||
| Net interest expense |
(
|
(
|
||||||||||||||||||||||||
| Share-based compensation (a) |
(
|
(
|
||||||||||||||||||||||||
| Amortization of intangible assets |
(
|
(
|
||||||||||||||||||||||||
| Other, net (b) |
|
(
|
||||||||||||||||||||||||
| Earnings before taxes | $ |
|
$ |
|
||||||||||||||||||||||
______________________________________
| Notes: |
2022 Sales and Operating Earnings for the Diagnostic Products and Medical Devices reportable segments have been updated to reflect the internal transfer of the Acelis Connected Health business from Diagnostic Products to Medical Devices on January 1, 2023.
|
||||
| (a) |
Approximately
|
||||
| (b) |
Other, net for the three months ended March 31, 2022 includes $
|
||||
Note 15 — Subsequent Event
On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $
20
per common share, which equated to a purchase price of approximately $
850
million. The acquisition was funded with cash on hand. CSI sells an atherectomy system used in treating peripheral and coronary artery disease. The acquisition adds complementary technologies to Abbott’s portfolio of vascular device offerings. The transaction will be accounted for as a business combination. Abbott has begun the process of measuring, as of the acquisition date, the acquired assets and assumed liabilities. Preliminary purchase price allocation estimates will be disclosed in Abbott’s Form 10-Q for the period ending June 30, 2023.
19
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Financial Review — Results of Operations
Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are medical devices, diagnostic testing products, nutritional products and branded generic pharmaceuticals.
The following tables detail sales by reportable segment for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.
| Net Sales to External Customers | ||||||||||||||||||||||||||||||||
| (in millions) |
Three Months Ended
March 31, 2023 |
Three Months Ended
March 31, 2022 |
Total
Change |
Impact of
Foreign Exchange |
Total Change
Excl. Foreign Exchange |
|||||||||||||||||||||||||||
| Established Pharmaceutical Products | $ | 1,189 | $ | 1,147 | 3.7 | % | (7.4) | % | 11.1 | % | ||||||||||||||||||||||
| Nutritional Products | 1,967 | 1,894 | 3.8 | (3.9) | 7.7 | |||||||||||||||||||||||||||
| Diagnostic Products | 2,688 | 5,257 | (48.9) | (1.8) | (47.1) | |||||||||||||||||||||||||||
| Medical Devices | 3,900 | 3,594 | 8.5 | (3.9) | 12.4 | |||||||||||||||||||||||||||
| Total Reportable Segments | 9,744 | 11,892 | (18.1) | (3.3) | (14.8) | |||||||||||||||||||||||||||
| Other | 3 | 3 | n/m | n/m | n/m | |||||||||||||||||||||||||||
| Net Sales | $ | 9,747 | $ | 11,895 | (18.1) | (3.3) | (14.8) | |||||||||||||||||||||||||
| Total U.S. | $ | 3,928 | $ | 4,937 | (20.4) | — | (20.4) | |||||||||||||||||||||||||
| Total International | $ | 5,819 | $ | 6,958 | (16.4) | (5.7) | (10.7) | |||||||||||||||||||||||||
______________________________________
| Notes: |
The Acelis Connected Health business was internally transferred from Diagnostic Products to Medical Devices on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Diagnostic Products to Medical Devices.
|
||||
| In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. | |||||
| n/m = Percent change is not meaningful | |||||
The 14.8 percent decrease in total net sales during the first three months of 2023, excluding the impact of foreign exchange, reflected the decrease in demand for Abbott’s rapid diagnostic tests to detect COVID-19, partially offset by higher growth across other businesses. Abbott’s COVID-19 testing-related sales totaled approximately $730 million during the first quarter of 2023 and approximately $3.3 billion during the first quarter of 2022. Excluding the impact of COVID-19 testing-related sales, Abbott’s total net sales increased 4.9 percent. Excluding the impacts of COVID-19 testing-related sales and foreign exchange, Abbott’s total net sales increased 9.4 percent. Abbott’s net sales were unfavorably impacted by changes in foreign exchange rates in the first quarter as the relatively stronger U.S. dollar decreased total international sales by 5.7 percent and total sales by 3.3 percent.
Due to the unpredictability of demand for COVID-19 tests, the future extent to which COVID-19 will have a material effect on Abbott’s business, financial condition or results of operations is uncertain.
20
The table below provides detail by sales category for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.
| (in millions) |
March 31,
2023 |
March 31,
2022 |
Total
Change |
Impact of
Foreign Exchange |
Total Change
Excl. Foreign Exchange |
|||||||||||||||||||||||||||
| Established Pharmaceutical Products — | ||||||||||||||||||||||||||||||||
| Key Emerging Markets | $ | 912 | $ | 906 | 0.7 | % | (7.6) | % | 8.3 | % | ||||||||||||||||||||||
| Other Emerging Markets | 277 | 241 | 15.0 | (6.8) | 21.8 | |||||||||||||||||||||||||||
| Nutritionals — | ||||||||||||||||||||||||||||||||
| International Pediatric Nutritionals | 465 | 509 | (8.6) | (4.7) | (3.9) | |||||||||||||||||||||||||||
| U.S. Pediatric Nutritionals | 459 | 338 | 36.1 | — | 36.1 | |||||||||||||||||||||||||||
| International Adult Nutritionals | 690 | 708 | (2.6) | (7.0) | 4.4 | |||||||||||||||||||||||||||
| U.S. Adult Nutritionals | 353 | 339 | 3.9 | — | 3.9 | |||||||||||||||||||||||||||
| Diagnostics — | ||||||||||||||||||||||||||||||||
| Core Laboratory | 1,182 | 1,184 | (0.2) | (5.3) | 5.1 | |||||||||||||||||||||||||||
| Molecular | 147 | 420 | (65.0) | (1.0) | (64.0) | |||||||||||||||||||||||||||
| Point of Care | 134 | 128 | 4.7 | (1.0) | 5.7 | |||||||||||||||||||||||||||
| Rapid Diagnostics | 1,225 | 3,525 | (65.3) | (0.8) | (64.5) | |||||||||||||||||||||||||||
| Medical Devices — | ||||||||||||||||||||||||||||||||
| Rhythm Management | 527 | 524 | 0.4 | (3.6) | 4.0 | |||||||||||||||||||||||||||
| Electrophysiology | 505 | 485 | 3.9 | (4.9) | 8.8 | |||||||||||||||||||||||||||
| Heart Failure | 281 | 250 | 12.4 | (1.2) | 13.6 | |||||||||||||||||||||||||||
| Vascular | 617 | 619 | (0.2) | (4.1) | 3.9 | |||||||||||||||||||||||||||
| Structural Heart | 461 | 411 | 12.2 | (4.2) | 16.4 | |||||||||||||||||||||||||||
| Neuromodulation | 196 | 179 | 9.4 | (1.8) | 11.2 | |||||||||||||||||||||||||||
| Diabetes Care | 1,313 | 1,126 | 16.6 | (4.4) | 21.0 | |||||||||||||||||||||||||||
Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $29 million of sales for the first quarter of 2022 were moved from Rapid Diagnostics to Heart Failure.
21
Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets for Established Pharmaceutical Products increased 8.3 percent in the first three months of 2023, led by growth in several countries, including Brazil, China and southeast Asia, and across several therapeutic areas, including cardio-metabolic, respiratory, and central nervous system/pain management. Other Emerging Markets, excluding the effect of foreign exchange, increased by 21.8 percent in the first three months of 2023.
Excluding the impact of foreign exchange, total Nutritional Products sales in the first three months of 2023 increased
7.7 percent
. In
U.S. Pediatric Nutritionals, the 36.1 percent increase in sales in the first three months of 2023 refle
cts the impact of the unfavorable effects of the voluntary recall of certain infant formula products in the first quarter of 2022, partially offset by a decrease in 2023 Pedialyte
®
sale
s. Excluding the effect of foreign exchange, the 3.9 percent decrease in International Pediatric Nutritional sales in the first three months of 2023 primarily reflects the impact of exiting the pediatric nutrition business in China, partially offset by growth in several other markets
.
Excluding the effect of foreign exchange, the increases of 3.9 percent in U.S. Adult Nutritionals and 4.4 percent in International Adult Nutritionals in the first three months of 2023 were led by growth of Ensure
®
products.
The 47.1 percent decrease in Diagnostic Products sales in the first three months of 2023, excluding the impact of foreign exchange, was driven by lower demand for COVID-19 tests. In Rapid Diagnostics, sales decreased 64.5 percent in the first three months of 2023, excluding the effect of foreign exchange, due to lower demand for COVID-19 tests. In the first three months of 2023 and 2022, Rapid Diagnostics COVID-19 testing-related sales were $704 million and $3.0 billion, respectively. In the first three months of 2023, Rapid Diagnostics sales increased 5.1 percent, excluding COVID-19 testing-related sales, and increased 8.0 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
In Core Laboratory Diagnostics, sales increased 5.1 percent in the first three months of 2023, excluding the effect of foreign exchange, due to the higher volume of routine diagnostic testing performed in hospitals and other laboratories, partially offset by lower test sales for the detection of COVID-19 IgG and IgM antibodies. In the first three months of 2023 and 2022, Core Laboratory Diagnostics COVID-19 testing-related sales were $6 million and $28 million, respectively. In the first three months of 2023, Core Laboratory Diagnostics sales increased 1.7 percent, excluding COVID-19 testing-related sales, and increased 7.1 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
The 64.0 percent decrease in Molecular Diagnostics sales in the first three months of 2023, excluding the effect of foreign exchange, was driven by
lower demand for laboratory-based molecular tests for COVID-19 as well as lower demand for respiratory testing compared to significantly higher-than-usual demand in the first quarter of 2022.
In the first three months of 2023 and 2022, Molecular Diagnostics COVID-19 testing-related sales were $20 million and $246 million, respectively. In the first three months of 2023, Molecular Diagnostics sales decreased 27.1 percent, excluding COVID-19 testing-related sales, and decreased 24.8 percent, excluding the impact of foreign exchange and COVID-19 testing-related sales.
Excluding the effect of foreign exchange, total Medical Devices sales grew 12.4 percent in the first three months of 2023, led by double-digit growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation. Higher Diabetes Care sales were driven by continued growth of FreeStyle Libre
®
, Abbott’s continuous glucose monitoring system, in the U.S. and internationally. FreeStyle Libre sales totaled $1.2 billion in the first three months of 2023, which reflected a 25.4 percent increase, excluding the effect of foreign exchange, over the first three months of 2022 when FreeStyle Libre sales totaled $1.0 billion.
During the first three months of 2023, procedure volumes increased across the cardiovascular and neuromodulation businesses. In Structural Heart, the 16.4 percent increase in sales, excluding the effect of foreign exchange, reflects an acceleration in the growth of the MitraClip
®
product along with contributions from recently launched products, including Amulet
®
, Navitor
®
, and TriClip
®
. In Vascular, the 3.9 percent increase in sales, excluding the impact of foreign exchange, during the first three months of 2023 primarily reflects double-digit growth in endovascular sales.
22
In Electrophysiology, the 8.8 percent increase in sales, excluding the effect of foreign exchange, primarily reflects higher procedure volumes in various European countries and the U.S. In Neuromodulation the 11.2 percent increase in sales, excluding the effect of foreign exchange, was driven by the recent launch of the Eterna
TM
rechargeable spinal cord stimulation system for the treatment of chronic pain along with market growth compared to the prior year period.
In the first three months of 2023, Medical Devices received various product approvals. In January 2023, Abbott announced that the U.S. Food and Drug Administration (FDA) had approved Navitor, Abbott's second-generation transcatheter aortic valve implantation system to treat people with severe aortic stenosis who are at high or extreme risk for open-heart surgery. In March 2023, Abbott's Freestyle Libre continuous glucose monitoring system received U.S. FDA clearance for integration with automated insulin delivery systems. In March 2023, the U.S. FDA approved Abbott's Epic
®
Max stented tissue valve to treat people with aortic regurgitation or stenosis.
The gross profit margin percentage was 50.5 percent for the first quarter of 2023 compared to 53.8 percent for the first quarter of 2022. The decrease in the first quarter of 2023 reflects the unfavorable effects of lower sales of COVID-19 tests, foreign exchange, and higher costs for various manufacturing inputs, partially offset by the impact in 2022 of the voluntary product recall in the Nutritional business and the impact in 2023 of gross margin improvement initiatives.
Research and development (R&D) expenses decreased $43 million, or 6.2 percent, in the first quarter of 2023 compared to the prior year. The decrease in R&D expenses in the first quarter of 2023 was primarily driven by the timing of spending on various projects and the favorable impact of foreign exchange.
Selling, general and administrative expenses decreased $25 million, or 0.9 percent, in the first quarter of 2023 compared to the prior year as higher selling and marketing spending to drive growth across various businesses was offset by the favorable impact of foreign exchange and the nonrecurrence of 2022 expenses related to the product recall in the Nutritional segment.
Other (Income) Expense, net
Other income, net increased from $78 million of income in the first quarter of 2022 to $111 million of income in the first quarter of 2023. Th
e increase in
the first quarter of 2023 reflects higher income in 2023 related to the non-service cost components of net pension and post-retirement medical benefit costs.
Interest Expense, net
Interest expe
nse, net decreased $65 million
in the first quarter of 2023 due to the impact of higher interest rates on interest income, partially offset by the impact of interest rate hedge contracts related to certain fixed-rate debt.
Taxes on Earnings
Taxes on earnings reflect the estimated annual effective rates and include charges for interest and penalties. In the first three months of 2023 and 2022, taxes on earnings include approximately $3 million and $30 million, respectively, in excess tax benefits associated with share-based compensation. In the first three months of 2023 and 2022, taxes on earnings also include approximately $22 million and $30 million, respectively, of tax expense as the result of the resolution of various tax positions related to prior years.
Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease approximately $75 million to $80 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters.
23
Liquidity and Capital Resources March 31, 2023 Compared with December 31, 2022
The decrease in cash and cash equivalents from $9.9 billion at December 31, 2022 to $9.2 billion at March 31, 2023 primarily reflects the payment of dividends, share repurchases and capital expenditures, partially offset by the cash generated from operations in the first three months of 2023. Working capital was $9.8 billion at March 31, 2023 and $9.7 billion at December 31, 2022. The increase in working capital in 2023 primarily reflects an increase in inventory and a decrease in accounts payable, partially offset by a decrease in cash and cash equivalents.
In the Condensed Consolidated Statement of Cash Flows, Net cash from operating activities for the first three months of 2023 totaled approximately $1.1 billion, which reflects a decrease of $922 million from the prior year. The decrease is primarily due to a decline in operating earnings, partially offset by the timing of the collection of trade receivables and a reduction in cash taxes paid. In the first three months of 2023, Net cash from operating activities includes $282 million of pension contributions and the payment of cash taxes of approximately $122 million. In the first three months of 2022, Net cash from operating activities includes $334 million of pension contributions and the payment of cash taxes of approximately $195 million.
On March 15, 2022, Abbott repaid the $750 million outstanding principal amount of its 2.55% Notes upon maturity.
In September 2019, the board of directors authorized the early redemption of up to $5 billion of outstanding long-term notes.
As of March 31, 2023, $2.15 billion of the $5 billion authorization remains available.
At March 31, 2023, Abbott’s long-term debt rating was AA- by Standard & Poor’s Corporation and A1 by Moody’s Investors Service. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including lines of credit of $5.0 billion which expire in 2025.
In the first quarter of 2023, Abbott repurchased approximately 3 million of its common shares for $300 million.
As of March 31, 2023, $2.134 billion remains available for repurchase under the share repurchase program authorized by the board of directors in December 2021.
In the first quarter of 2023, Abbott declared a quarterly dividend of $0.51 per share on its common shares, which represents an increase of 8.5 percent over the $0.47 per share dividend declared in the first quarter of 2022.
Business Acquisition
On April 27, 2023, Abbott completed the acquisition of Cardiovascular Systems, Inc. (CSI) for $20 per common share, which equated to a purchase price of approximately $850 million. The acquisition was funded with cash on hand. CSI sells an atherectomy system used in treating peripheral and coronary artery disease. The acquisition adds complementary technologies to Abbott’s portfolio of vascular device offerings. The transaction will be accounted for as a business combination.
Legislative Issues
Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2022 Annual Report on Form 10-K.
Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements
Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions that any forward-looking statements made by Abbott are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
24
PART I. FINANCIAL INFORMATION
Item 4.
Controls and Procedures
(a)
Evaluation of disclosure controls and procedures.
The Chief Executive Officer, Robert B. Ford, and Chief Financial Officer, Robert E. Funck, Jr., evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
(b)
Changes in internal control over financial reporting.
During the quarter ended March 31, 2023, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
Abbott is involved in various claims, legal proceedings and investigations, including those described in our Annual Report on Form 10-K for the year ended December 31, 2022.
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
(c)
Issuer Purchases of Equity Securities
| Period |
(a) Total
Number of Shares (or Units) Purchased |
(b) Average
Price Paid per Share (or Unit) |
(c) Total Number
of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs |
(d) Maximum
Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs |
|||||||||||||||||||||||||
| January 1, 2023 - January 31, 2023 | — |
(1)
|
$ | — | — | $ | 2,434,092,348 |
(2)
|
|||||||||||||||||||||
| February 1, 2023 - February 28, 2023 | 600,000 |
(1)
|
100.933 | 600,000 | 2,373,532,278 |
(2)
|
|||||||||||||||||||||||
| March 1, 2023 - March 31, 2023 | 2,369,830 |
(1)
|
101.037 | 2,369,830 | 2,134,092,391 |
(2)
|
|||||||||||||||||||||||
| Total | 2,969,830 |
(1)
|
101.016 | 2,969,830 | $ | 2,134,092,391 |
(2)
|
||||||||||||||||||||||
______________________________________
1.
These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.
2.
On December 10, 2021, the board of directors authorized the repurchase of up to $5 billion of Abbott common shares, from time to time.
25
Item 6.
Exhibits
| Exhibit No. | Exhibit | |||||||
| 3.1 | ||||||||
| 10.1 | ||||||||
| 31.1 | ||||||||
| 31.2 | ||||||||
| Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934. | ||||||||
| 32.1 | ||||||||
| 32.2 | ||||||||
| 101 | The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Inline XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Shareholders’ Investment; (v) Condensed Consolidated Statement of Cash Flows; and (vi) Notes to the Condensed Consolidated Financial Statements. | |||||||
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document and included in Exhibit 101). | |||||||
26
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| ABBOTT LABORATORIES | ||||||||
| By: | /s/ ROBERT E. FUNCK, JR. | |||||||
| Robert E. Funck, Jr. | ||||||||
|
Executive Vice President, Finance
and Chief Financial Officer |
||||||||
|
Date: May 4, 2023
|
||||||||
27
TABLE OF CONTENTS
Part I. Financial InformationprintItem 4. Controls and ProceduresprintPart II. Other InformationprintItem 1. Legal ProceedingsprintItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsprintItem 6. Exhibitsprint